- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Omnipaque sales top half-billion mark
Sterling Winthrop's x-ray contrast agent Omnipaque recorded global sales of more than $500 million last year, according to a listing of the world's 100 best selling drugs published in the May issue of Med Ad News. The agenthad worldwide sales of $505
Sterling Winthrop's x-ray contrast agent Omnipaque recorded global sales of more than $500 million last year, according to a listing of the world's 100 best selling drugs published in the May issue of Med Ad News. The agenthad worldwide sales of $505 million and was ranked 37th on thepublication's list.
The majority of Omnipaque's revenue derived from U.S. sales,which were pegged at $480 million in 1993 -- up 1% from the $475million in sales recorded the year before.
The next best selling imaging agent on the list was Bristol-MyersSquibb's Isovue. The x-ray imaging product recorded worldwidesales of $310 million in 1993, down 7.4% from the $335 millionregistered in 1992. Isovue had U.S. sales of $305 million in 1993and $320 million the year before.
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.
